Neuro.Al Algorithm
by TeraRecon (a ConcertAI company)
· Based in United States →
— AI-Powered Advanced Visualization for Neurological Imaging
Subscription-based
Regulatory Status Disclosed
Overview
The Neuro.Al Algorithm, also known as TeraRecon Neuro Algorithm or Neuro.AI Algorithm, is an AI-powered image processing software designed for the analysis of functional, dynamic, and derived imaging datasets acquired with CT or MRI. It provides capabilities for dynamic brain perfusion analysis, calculating parameters related to brain tissue perfusion, vascular assessment, and tissue blood volume. This algorithm is often integrated into TeraRecon’s broader advanced visualization platforms, such as the Eureka Clinical AI Platform and Intuition system, to enhance diagnostic precision and streamline workflows for neurological assessments. It can be deployed as a standalone Microsoft Windows executable or as a containerized application on off-the-shelf hardware or cloud platforms, acquiring and exporting data via DICOM-compliant devices.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Analysis of functional, dynamic, and derived imaging datasets (CT/MRI)
- Dynamic brain perfusion analysis
- Calculation of brain tissue perfusion, vascular assessment, and tissue blood volume parameters
- Integration with TeraRecon's Intuition and Eureka AI Results Explorer platforms
- Standalone deployment as a Windows executable or containerized application
- DICOM compliant data acquisition and export
- Motion correction capabilities
- AI-driven automations to enhance diagnostic precision
- Automated CT perfusion maps for brain function assessment
- Support for neurovascular emergencies like stroke, ICH, and LVO
Use Cases
- Diagnosis and treatment planning for various neurological conditions
- Assessment of neurovascular diseases
- Analysis of neurodegenerative diseases, including Alzheimer's and dementia
- Gaining insights into brain tumor vascularization and oxygenation
- Emergency readiness and triage for hemorrhagic and ischemic neurological cases (e.g., stroke)
- Monitoring disease progression and facilitating follow-up care in neurology
What Physicians Need to Know
Stroke Detection Speed
AI algorithms can process imaging data in under 30 seconds, providing immediate alerts to medical teams, and can analyze CT scans in 1-6 minutes, significantly reducing door-to-notification times by 30-52% compared to traditional workflows.
Brain MRI/CT Analysis
AI can rapidly scan hundreds of images from CT and MRI, accurately segmenting tissues, analyzing contrast-enhanced scans for perfusion and lesions, interpreting DTI data, and comparing scans over time to track disease progression. It can also provide automated brain volumetric analysis, quantifying 83 brain regions in under 10 minutes.
EEG Interpretation AI
AI programs can interpret EEGs with expert-level accuracy, distinguishing normal from abnormal recordings and classifying abnormalities into subtypes like focal epileptiform or generalized non-epileptiform activity, with some models achieving an AUC between 0.89 and 0.96.
Seizure Detection
AI systems can detect and classify seizures from EEG signals, including rare and complex forms, by analyzing brain interactions and integrating multiple data sources, demonstrating improved accuracy over traditional methods. Real-time monitoring with multi-modal sensors and AI can predict seizure events and send alerts.
Neurodegenerative Disease Screening
AI offers transformative potential by analyzing complex multimodal data (neuroimaging, genetics, speech, behavioral metrics) to identify subtle early signs of neurodegeneration, with some models achieving 95% accuracy in detecting Alzheimer's disease biomarkers from vocal cognitive tests.
Large Vessel Occlusion Detection
AI algorithms provide fast and accurate detection of LVOs in acute ischemic stroke patients, achieving sensitivities of 86-95% and specificities of 94-97%, and can significantly improve detection rates for early-career physicians.
Triage Prioritization Speed
AI algorithms can prescreen head CT exams for acute neurological events 150 times faster than humans, completing image processing and inference in an average of 1.2 seconds, enabling rapid prioritization of urgent cases and improving patient flow.
ASPECTS Score Automation
AI tools can automatically calculate the Alberta Stroke Program Early CT Score (ASPECTS) to quantify ischemic changes on non-contrast CT scans, aiding in treatment decisions and improving the individual sensitivity of physicians.
Mobile Notification System
AI-powered systems can provide real-time alerts to care teams upon detection of critical findings like LVOs (within 6 minutes of CT acquisition) or predicted seizure events, often integrating with mobile devices and wearables for enhanced patient management.
Physician Tip
Leverage AI as an invaluable assistive tool to augment diagnostic capabilities and accelerate time-sensitive interventions, particularly in stroke and seizure management. While AI offers enhanced accuracy and speed in image interpretation and pattern detection, always integrate its findings with comprehensive clinical judgment and patient context. Utilize AI for screening subtle changes in neuroimaging and EEG that might be challenging to detect manually, and understand the algorithm's performance metrics (sensitivity, specificity) to inform clinical decision-making.
Seamless integration with existing hospital Picture Archiving and Communication Systems (PACS) and Electronic Health Records (EHR) is crucial for optimizing workflow. The system should support interoperability with various imaging modalities (CT, MRI, EEG) to ensure a unified data flow. Real-time alert systems, potentially via mobile notifications, should be a core component to facilitate rapid communication among care teams. Prioritize solutions with robust data security and privacy protocols to comply with healthcare regulations and maintain patient confidentiality.
Details
| Category | Neurology AI |
| Pricing | Subscription-based |
| Deployment | On-premise (Windows executable) or cloud (containerized application, e.g., Docker) |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status |
1 AI-estimated The Neuro.AI Algorithm (K200750) was cleared by the FDA on November 6, 2020, as a Class II radiology device (Product Code LLZ) for image processing. |
| Integrations | |
| EHR | Not specified |
| Specialties | Neurology, Neurosurgery, Radiology |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Neuro.Al Algorithm
Press & Coverage
Radiology AI Companies - X-ray Interpreter
Neuro.Al Algorithm | TeraRecon, Inc. radiology AI profile
The Neuro.AI Algorithm by TeraRecon, Inc. is an FDA-cleared AI-powered medical imaging software released on November 6, 2020, that analyzes brain perfusion images from CT or MRI to help assess brain perfusion and vascular health.
2020-11
PMC
Artificial Intelligence and Machine Learning in the Diagnosis and Management of Stroke: A Narrative Review of United States Food and Drug Administration-Approved Technologies - PMC
This review from May 2023 lists the Neuro.AI Algorithm by TeraRecon as an FDA 510(k) cleared technology from November 2020, designed to detect changes in brain perfusion from CT or MRI scans.
2023-05
ConcertAI
ConcertAI's TeraRecon Releases AI-Assisted Clinical Workflow Solution, TeraRecon Neuro
In October 2022, ConcertAI's TeraRecon announced the release of TeraRecon Neuro, an AI-driven clinical workflow solution for neurovascular emergencies, offering automatic screening for suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO).
2022-10
Diagnostic Imaging
TeraRecon Launches AI-Powered Neuro Suite | Diagnostic Imaging
TeraRecon launched its AI-powered Neuro Suite in April 2023, providing radiologists with access to various AI-powered neuroimaging modalities from leading vendors for the diagnosis of degenerative cerebral pathologies and insights into brain tumors and neurovascular function.
2023-04
ConcertAI
ConcertAI's TeraRecon Adds the Releases of an AI-Assisted Clinical Suite Solution, Neuro Suite to Provide Comprehensive Solutions for Neurological Disorders
In April 2023, ConcertAI's TeraRecon released the Neuro Suite, an AI-driven clinical suite designed for disease triage, differential diagnostic insights, and care activation in various neurological disease states.
2023-04
AuntMinnie
TeraRecon releases neuro software package - AuntMinnie
AuntMinnie reported in October 2022 on the release of TeraRecon Neuro, a software package for diagnosing and treating neurovascular emergencies, which includes AI-driven clinical workflow and automated CT perfusion maps.
2022-10
Journal of Medicine and Life Science
Machine learning application in ischemic stroke diagnosis, management, and outcome prediction: a narrative review - Journal of Medicine and Life Science
A December 2023 review highlights the Neuro.AI Algorithm by TeraRecon as a Class II medical device used in the USA for assessing ASPECTS/perfusion in CT scans for large vessel occlusion detection in ischemic stroke.
2023-12
SciOpen
Implications of Artificial Intelligence in Stroke Intervention and Care - SciOpen
An April 2025 article mentions the Neuro.AI algorithm by TeraRecon as an AI-powered tool that detects changes in brain perfusion from MRI or CT scans and integrates with CT perfusion 4D for automated neuro perfusion analysis.
2025-04
Videos
Product demos, reviews, and walkthroughs for Neuro.Al Algorithm.
Loading videos...
Frequently Asked Questions
The Neuro.AI Algorithm is designed to integrate seamlessly with standard imaging systems (e.g., PACS) or Electronic Health Records (EHRs), providing AI-powered analysis of neurological data. It's primarily intended for applications such as early disease detection, lesion segmentation, or predicting disease progression in conditions like stroke, multiple sclerosis, or neurodegenerative disorders.
The Neuro.AI Algorithm would typically require FDA clearance (or equivalent international regulatory body approval) as a medical device, depending on its classification. It ensures HIPAA compliance through robust data anonymization, encryption protocols, and secure data handling practices, often processing data locally or within secure, compliant cloud environments.
While highly accurate, the algorithm's performance can be influenced by data quality, image artifacts, or rare disease presentations it wasn't extensively trained on. Potential biases may arise from training data demographics, and ethical considerations include ensuring equitable access and avoiding over-reliance that could diminish clinical judgment.
Current alternatives primarily involve traditional human interpretation of imaging and clinical data by neurologists, neuroradiologists, and other specialists. This includes manual lesion measurement, subjective assessment of disease progression, and reliance on established clinical scales and diagnostic criteria without AI augmentation.
Pricing models often vary, ranging from subscription-based fees per study or per user, to tiered licensing based on volume or features. The expected ROI can come from improved diagnostic efficiency, earlier intervention leading to better patient outcomes, reduced physician burnout, and potentially optimized resource allocation.
The algorithm is typically validated through rigorous clinical trials and retrospective studies against ground truth data, often involving expert consensus. While deep learning models can be complex, efforts are made to provide explainable AI features, such as heatmaps or confidence scores, to offer insights into its reasoning.
Providers typically offer comprehensive support, including initial training for clinical staff, technical assistance, and regular software updates to improve performance, add new features, and address any identified issues. Continuous monitoring and maintenance are crucial for optimal long-term operation and compliance.
Suggest an Edit →
| Last Verified: 2026-04-19 | First Added: 2026-04-19